MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium
Complete the form below to unlock access to ALL audio articles.
The Drug Safety Executive Council (DSEC), an industry membership run by Cambridge Healthtech Associates (CHA), together with Metanomics Health GmbH, a BASF Group company, and leader in offering targeted and non-targeted metabolite profiling to healthcare customers, have announced a new project as part of DSEC's Technology Evaluation Consortium.
The goal of the project is to assess the scientific and economic utility of MetaMap® Tox, a platform that uses metabolite patterns of rat plasma for early recognition of toxicity for new drugs. Nine leading biopharmaceutical companies, whose names are undisclosed, will participate in the collaborative evaluation of MetaMap® Tox.
"The MetaMap® Tox solution is an exciting new tool to assess the safety of a compound in the development phase. This project supports CHA's mission of streamlining the research and development process," said Eric Glazer, Managing Director, DSEC.
"MetaMap® Tox offers the unique possibility to monitor systemic toxicological response of rats to new chemical entities based on < 100 established specific metabolic patterns indicative for toxicological modes of action. The benefit is to better and earlier identify the potential safety risks for a test compound and help guiding steps to mitigate risk in early drug development," said Tim Boelke, Managing Director, Metanomics Health GmbH.
Boelke continued, "We are therefore excited that Metanomics Health is one of a select few technology providers invited to participate in the DSEC Technology Evaluation Consortium."
